The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
Open accessAbstract
Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacological inhibition to reduced tumorigenicity. However, the clinical relevance of targeting PTK2 still remains to be proven. Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel–Lindau and cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 (cereblon-based) degrades PTK2 with a median DC 50 of 30 nM to >80% across a panel of 11 HCC cell lines. Despite effective PTK2 degradation, these compounds did not phenocopy the reported antiproliferative effects of PTK2 depletion in any of the cell lines tested. By disclosing these compounds, we hope to provide valuable tools for the study of PTK2 degradation across different biological systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,554
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Flagged first, then by citations
Research works printed but not linked: 3
- Lark A. L., 2003, Clin. Cancer Res., 9, 215
- Dodson E. J., 1997, Methods in Enzymology, 277, 620
- Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. Buster, version 2.11.5; Global Phasing Ltd: Cambridge, United Kingdom, 2011.
Cited by
Sorted by citations
Items 101–146 of 146
Khan, M. Z. I., Nazli, A., Pan, Y., & Chen, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220803112409 · Cited by 7
FAK inhibitors in cancer, a patent review – an update on progress
Ye, Y., Cao, Y., Xu, L., Wang, H.-C., Liu, X., & Zhu, H. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2368742 · Cited by 6
Zhao, W., Xu, X., An, S., Wu, J., Wang, H., Luo, J., Yuan, Y., & Li, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114200 · Cited by 7
Guo, C., Li, Q., Xiao, J., Ma, F., Xia, X., & Shi, M. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2135601 · Cited by 5
E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
Basu, B., Kal, S., Karmakar, S., Basu, M., & Ghosh, M. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122333 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Law, R. P., Nunes, J., Chung, C., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202109237 · Cited by 6
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
Wei, W., Li, G., Hu, Z., Hu, X., Hu, R., Zhang, Q., Li, X., Yang, T., Gao, J., Cao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00921 · Cited by 4
Zhang, X., Li, S., SONG, M., Chen, Y., Chang, L., Liu, Z., Dai, H., Wang, Y., Yang, G., JIANG, Y., et al. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.046231 · Cited by 5
FAK: A Potential Target for Cancer Therapy
Zhang, C., & Rao, Y. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00184 · Cited by 4
Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors
Gupta, N., Trainor, N. B., Radwan, M., Nguyen, S., Duncan, L. J., Tang, A. X., Beveridge, J. G., Silke, N., Yousef, J. M., Bilgilier, C., et al. (2026) · Communications Chemistry · doi:10.1038/s42004-025-01871-x · Cited by 3
Self-citationBhuyan, A. J., Bharali, S. J., Sharma, A., Dutta, D., Gogoi, P., & Saikia, L. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c00658 · Cited by 3
Xiao, Z., Song, S., Chen, D., van Merkerk, R., van der Wouden, P. E., Cool, R. H., Quax, W. J., Poelarends, G. J., Melgert, B. N., & Dekker, F. J. (2021) · Angewandte Chemie · doi:10.1002/ange.202101864 · Cited by 4
PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
Feral, A., Laconde, G., Amblard, M., & Masurier, N. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000148 · Cited by 3
Target Protein Localisation and Its Impact on PROTAC-Mediated DegradationPreprint
Simpson, L. M., Glennie, L., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4006704 · Cited by 3
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint
Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695.v1 · Cited by 3
Self-citationGollner, A., Heine, C., & Hofbauer, K. S. (2023) · ChemMedChem · doi:10.1002/cmdc.202300031 · Cited by 2
Shi, Y., Ju, M., Xue, N., Zhang, Y., Liang, L., Sun, X., & Di, X. (2024) · Medicine · doi:10.1097/md.0000000000037362 · Cited by 4
Bhuyan, A. J., Nath, P. P., Bharali, S. J., & Saikia, L. (2024) · RSC Advances · doi:10.1039/d4ra00001c · Cited by 1
Liu, C., Xu, X., Biao, Y., Wang, Y., & Zhang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109017 · Cited by 1
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1
On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases
Weckesser, J., Miletić, N., Sivashanmugam, S. A., Ohmayer, U., Steger, M., Shashikadze, B., Gehrtz, P., Lopez, A. U., Wegener, A. A., Dietz, T. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00383 · Cited by 1
Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation
Kumar, V., Parate, S., Ro, H., Jung, T. S., & Lee, K. W. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151001 · Cited by 1
Abdul‐Rasheed, O. F., Hussein, A. N., Mahdi, M. F., & Raauf, A. M. R. (2020) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.11.1.22 · Cited by 1
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint
Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695 · Cited by 1
Self-citationMIF family proteins in lung diseases
Song, S. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.172449812
Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals Immunotherapeutic Value of FAK/PTK2Preprint
Shi, Y., Ju, M., Xue, N., Zhang, Y., Liang, L., Sun, X., & Di, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1413750/v1
A Structural and Biophysical Perspective of Degrader Activity Through Ternary Complex Formation
Gadd, M. S., & Aublette, M. C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch4
PROTAC Pharmaceutical Research and its Applications
Xu, Y. (2023) · International Journal of Biology and Life Sciences · doi:10.54097/ijbls.v2i3.8663
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Shogi, F., Gholamin, D., & Razzaghi‐Asl, N. (2024) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416524500601
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Star, R., Saikia, S., Bhuyan, A. J., Hussain, S., Konwar, D., & Saikia, L. (2025) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.70145
A Critical Assessment of Computer-Aided Approaches for Identifying FAK Inhibitors
Quispe, P. A., Lietha, D., León, I. E., & Lavecchia, M. J. (2025) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases3040027
Cheng, J., He, Y., Yuan, Y., Mu, Y., Zhao, X., Wu, F., Sayes, C. M., & Giesy, J. D. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c00371
BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
BindingDB (2024) · UC San Diego · doi:10.7270/q27948wc
BindingDB (2023) · UC San Diego · doi:10.7270/q2vm4h9b
BindingDB (2022) · UC San Diego · doi:10.7270/q24t6p31
BindingDB Entry 50016327: Selectivity through Targeted Protein Degradation (TPD).
BindingDB (2023) · UC San Diego · doi:10.7270/q22n568r
Metadata
- Authors
- Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., Koegl, M., McConnell, D. B., Pearson, M., Rieger, M., Rinnenthal, J., Roessler, V., Schrenk, A., Spina, M., Steurer, S., Trainor, N., Traxler, E., Wieshofer, C., Zoephel, A., & Ettmayer, P.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- University of Dundee (GB)
- Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria
- Corresponding author
- Ettmayer, Peter
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-02-09
- Volume
- 62
- Issue
- 5
- Pages
- 2508-2520
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2913179893
- Cited by
- 138
- References
- 49
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 17 · 2023: 15 · 2022: 25 · 2021: 31 · 2020: 22 · 2019: 6
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- focal adhesion kinase, PROTACs, cereblon ligands, hepatocellular carcinoma, protein degradation, antiproliferative activity
- MeSH terms
- Humans, Ligands, Recombinant Proteins, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Focal Adhesion Protein-Tyrosine Kinases, Focal Adhesion Kinase 1, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
